- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| Mi | Vocodia Holdings Corp.: Vocodia Announces Commitment Letter to Acquire a Majority of Privacy Pal LLC; Tech Industry Veteran Jason Melo to Serve as CEO | 179 | BOCA RATON, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vocodia Holdings Corp (OTC: VHAI) ("Vocodia" or the "Company"), a pioneer in AI-driven customer engagement solutions, today announced it has entered... ► Artikel lesen | ||
| Mi | 4D Molecular Therapeutics, Inc.: 4DMT Provides Company Update and Anticipated Development Milestones for 2026 | 96 | Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize... ► Artikel lesen | ||
| Mi | RYVYL Inc.: RYVYL Highlights Recent Developments for Merger Partner Roundtable that Advance Web3 Platform Traction | 50 | New Strategic Partnerships with The Hockey News and Expansion of Elite Journalist Network to 150+ Former Sports Illustrated Media Professionals SAN DIEGO, CA, Jan. 07, 2026 (GLOBE NEWSWIRE) -- RYVYL... ► Artikel lesen | ||
| Mi | Captivision Inc.: Captivision Announces Additional Extensions Granted by Nasdaq and Receipt of Additional Determination Letter; Extension Enables Audit Completion to Regain Compliance and Strategic Acquisition to create Montana Gold Inc. (Nasdaq: ... | 23 | MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Captivision Inc. ("Captivision" or the "Company") (Nasdaq: CAPT), today announced that it has been informed that the Nasdaq Hearings Panel (the "Panel") has... ► Artikel lesen | ||
| Mi | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts | 28 | - Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity-... ► Artikel lesen | ||
| Mi | Upexi Inc: Upexi Moves to High-Return Treasury Strategy | 38 | TAMPA, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ: UPXI), a leading Solana-focused digital asset treasury company and consumer brands owner, announced that it will implement a risk-adjusted... ► Artikel lesen | ||
| Mi | YIT invests in railway construction expertise and acquires Electric Power Finland Oy's railway services business | 54 | YIT Corporation Press Release January 7, 2026, at 3 p.m.
In line with its strategy, YIT seeks growth in rail infrastructure projects in Finland. To strengthen its railway construction expertise,... ► Artikel lesen | ||
| Mi | Volati AB: Volati acquires Interket Group | 91 | Volati has entered into an agreement to acquire all shares in Interket Group, a leading provider of self-adhesive labeling solutions with operations in Sweden, Germany, the Netherlands, and the United... ► Artikel lesen | ||
| Mi | HANZA AB: HANZA completes acquisition of BMK in Germany and carries out share issue in kind of approximately 17 million shares | 76 | HANZA AB (publ) has today completed the acquisition of the German company BMK Group GmbH ("BMK"), a leading European provider of advanced electronics manufacturing with turnover of approximately SEK... ► Artikel lesen | ||
| Mi | VR Resources Ltd.: VR Amends Brokered Private Placement Led by Centurion One Capital, amends Consolidation, and Continues Planning towards Exploration on its New Boston and Bonita Porphyry Projects in Nevada in 2026 | 87 | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Jan. 07, 2026 (GLOBE NEWSWIRE) -- VR Resources Limited ("VR" or the... ► Artikel lesen | ||
| Mi | Anterix Inc.: Anterix Appoints Ross Spero as Chief Product Officer | 82 | WOODLAND PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Anterix, Inc. (NASDAQ: ATEX) today announced the appointment of Ross Spero as Chief Product Officer. Spero will lead Anterix's product development... ► Artikel lesen | ||
| Mi | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | 121 | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | ||
| Mi | Palvella Therapeutics Inc.: Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs | 126 | Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA- , povorcitinib, ILUMYA®, ODOMZO- , REMICADE-... ► Artikel lesen | ||
| Mi | FibroGen, Inc.: FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum | 129 | Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq... ► Artikel lesen | ||
| Mi | Curium's Investigational New Drug Application Accepted by Center for Drug Evaluation in China | 180 | Curium's Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the Centre... ► Artikel lesen | ||
| Mi | Kamada Ltd.: Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance | 287 | 2026 Guidance Represents Year-Over-Year Increase of 13% in Revenues and 23% in Adjusted EBITDA Based on Mid-Point of 2025 Annual Guidance2026 Annual Guidance is Based Solely on Continued Organic GrowthCompany... ► Artikel lesen | ||
| Mi | OTC Markets Group Welcomes FUTURE FUELS INC to OTCQX | 108 | NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced FUTURE FUELS INC... ► Artikel lesen | ||
| Mi | Rezolute, Inc.: Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism | 228 | Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward... ► Artikel lesen | ||
| Mi | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | 100 | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | ||
| Mi | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline | 466 | U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter... ► Artikel lesen | ||
| Mi | Nobel Resources Corp.: First Diamond Drill Program Commences at Nobel's Flagship Cuprita Copper Project, Antofagasta Region, Chile | 84 | TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Nobel Resources Corp. (TSX - V: NBLC) (the "Company" or "Nobel") is pleased to announce commencement of mobilization by the Company's diamond drill contractor... ► Artikel lesen | ||
| Mi | BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI | 76 | NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines... ► Artikel lesen | ||
| Mi | Emerita Resources Corp.: Emerita Intersects 2.1m Grading 1.6% Copper, 0.85 g/t Gold, 32.11 g/t Silver and 1.4m Grading 5.8% Copper, 4.89 g/t Gold and 51.0 g/t Silver at El Cura | 48 | TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) (the "Company" or "Emerita") reports results from ongoing drilling of El Cura deposit. El Cura... ► Artikel lesen | ||
| Mi | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 | 163 | - Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026... ► Artikel lesen | ||
| Mi | OTC Markets Group Welcomes Bora Pharmaceuticals Co., Ltd. to OTCQX | 78 | NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Bora Pharmaceuticals... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .